EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> Acacia Pharma filed for an IPO. The British drug developer plans to list its stock on the Euronext exchange in Brussels. Acacia’s choice of Brussels comes a little more than two years after it dropped plans to raise £150 million ($210 million) in London. Statement (PDF)

> Sol-Gen Technologies raised $86.3 million on Nasdaq. The Israeli company will use the money to run phase 3 clinical trials in patients with acne and a form of the skin condition rosacea. Release  

> Adocia is seeking $200 million in damages from Eli Lilly. The arbitration claims relate to “Lilly’s misappropriation and improper use of Adocia’s confidential information and discoveries as well as Lilly’s breaches of several collaboration and confidentiality agreements,” the French biotech said in a statement. Adocia expects to receive a decision on the claims—and an earlier filing against Lilly—by the third quarter of 2018. Statement  


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Redx dosed the first patient in a phase 1/2a trial of Porcupine inhibitor RXC004. The trial is an early step in Redx’s attempts to bounce back from the financial difficulties that forced it to offload a BTK inhibitor to Loxo Oncology for $40 million. Release

> A phase 3 trial of Bavarian Nordic’s smallpox vaccine hit both its primary endpoints. The success of the second phase 3 trial positions the Danish drugmaker to file for FDA approval in the back half of the year. Statement

> TC BioPharm (TCB) entered into a collaboration with Nipro. The alliance is built upon TCB’s CAR-T platform. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.